Valuation: Ipsen

Market Cap 13.32B 15.18B 12.33B 11.35B 21.42B 1,461B 21.67B 147B 57.66B 717B 56.97B 55.73B 2,477B P/E 2026 *
14.8x
P/E 2027 * 14.4x
Enterprise Value 11.97B 13.65B 11.09B 10.2B 19.25B 1,314B 19.48B 132B 51.84B 644B 51.22B 50.11B 2,227B EV / Sales 2026 *
2.78x
EV / Sales 2027 * 2.42x
Free-Float
40.65%
Yield 2026 *
0.94%
Yield 2027 * 0.93%
1 day+1.00%
1 week-0.98%
Current month-2.54%
1 month+5.22%
3 months+1.00%
6 months+22.57%
Current year+35.89%
1 week 156.4
Extreme 156.4
161.3
1 month 155.5
Extreme 155.5
172.3
Current year 116.5
Extreme 116.5
172.7
1 year 102.8
Extreme 102.8
172.7
3 years 90.2
Extreme 90.2
172.7
5 years 77.76
Extreme 77.76
172.7
10 years 36.84
Extreme 36.84
172.7
Manager TitleAgeSince
Chief Executive Officer 59 30/06/2020
Chief Executive Officer 57 31/12/2019
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 61 29/08/2005
Chairman 68 21/11/2010
Director/Board Member 69 31/05/2012
Change 5-day change 1-year change 3-year change Capi.($)
+1.00%-0.98% - - 15.17B
+2.49%-0.55%+52.31%+153.42% 1,023B
+0.72%-2.78%+53.09%+48.84% 599B
+1.07%+3.27%+35.32%+80.11% 448B
+0.63%+0.94%+29.13%+21.91% 326B
+1.98%+0.77%+36.03%+38.03% 278B
+0.90%-0.94%+21.35%+16.79% 258B
-1.20%-0.11%-21.84%-41.31% 222B
+0.57%+1.61%+24.25%+57.03% 197B
-2.20%-0.85%+20.38%+62.97% 165B
Average +0.41%-0.38%+27.78%+48.64% 390.56B
Weighted average by Cap. +0.87%-1.18%+36.82%+72.99%

Financials

2026 *2027 *
Net sales 4.31B 4.91B 3.99B 3.67B 6.93B 473B 7.02B 47.68B 18.67B 232B 18.44B 18.04B 802B 4.53B 5.16B 4.19B 3.86B 7.28B 497B 7.37B 50.08B 19.6B 244B 19.37B 18.95B 842B
Net income 940M 1.07B 870M 801M 1.51B 103B 1.53B 10.39B 4.07B 50.56B 4.02B 3.93B 175B 954M 1.09B 883M 813M 1.53B 105B 1.55B 10.55B 4.13B 51.32B 4.08B 3.99B 177B
Net Debt -1.34B -1.53B -1.25B -1.15B -2.16B -148B -2.19B -14.87B -5.82B -72.36B -5.75B -5.63B -250B -2.35B -2.68B -2.17B -2B -3.77B -257B -3.82B -25.96B -10.16B -126B -10.04B -9.82B -436B
Logo Ipsen
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows: - oncology (69.2%); - neuroscience (20.3%); - rare diseases (10.5%). At the end of 2025, the group had 7 research and development centers located in France (2), the United Kingdom (2), China (2) and Ireland, and 5 manufacturing sites worldwide. Net sales are distributed geographically as follows: France (8%), Europe (31.7%), the United States (32.9%), North America (2.2%) and other (25.2%).
Employees
5,535
Date Price Change
21/07/26 €161.30 +1.00%
20/07/26 €159.70 +0.50%
17/07/26 €158.90 -0.50%
16/07/26 €159.70 +1.59%
15/07/26 €157.20 -1.32%
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
162.20EUR
Average target price
161.67EUR
Spread / Average Target
-0.33%

Quarterly revenue - Rate of surprise